FDA Approves Ferric Carboxymaltose for Mylan's ANDA217076
The FDA has approved Mylan's application for Ferric Carboxymaltose under ANDA217076.
Published: July 24, 2026
Updated: July 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Iron Deficiency Anemia
Company: Mylan
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
Mylan
Asset
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of Mylan's Ferric Carboxymaltose marks a significant regulatory milestone that enhances competition in the iron deficiency anemia treatment market. This development is crucial for pharma strategy teams to assess potential impacts on pricing and market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake and any competitive responses from other manufacturers in the iron deficiency space.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.